博客
Insilico Medicine Initiates First-in-Human Study of AI-discovered Drug
Insilico discovered a Novel disease mechanism, identified a Novel target, and designed a Novel molecule validated in preclinical experiments
We are very happy to be presenting our approach to generative chemistry and the Chemistry42 platform at the NVIDIA GTC 2021 and the application of this platform which enabled the nomination of a pre-clinical candidate for a novel target for idiopathic pulmonary fibrosis (IPF) in under 18 months.
AI-generated novel molecule for a novel target discovered with AI demonstrated efficacy in a broad therapeutic area and reached preclinical candidate stage in Idiopathic Pulmonary Fibrosis (IPF)